Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasm Metastasis 2Advanced Malignancies 2Urothelial Cancer 1Thyroid Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1KRAS p.G12C Mutant Advanced Solid Tumors 1Hematologic Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 16fludarabine 9Cytarabine 9venetoclax 8Mycophenolic Acid 8Busulfan 7fludarabine phosphate 6Whole-Body Irradiation 6Tacrolimus 5Daunorubicin 5Cyclosporine 5ruxolitinib 4ponatinib 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Etoposide 4blinatumomab 3asciminib 3Vincristine 3Prednisone 3Mercaptopurine 3Inotuzumab Ozogamicin 3Dexamethasone 3Azacitidine 3revumenib 2quizartinib 2pegfilgrastim 2nilotinib 2ibrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Midazolam × 90 days × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡